- AcuityMD is an AI-driven MedTech intelligence platform based in Boston, Massachusetts, valued at $955 million, that serves 16 of the top 20 MedTech companies globally and has identified over $34 billion in commercial pipeline opportunities.
- In April 2026, AcuityMD raised $80 million in a Series C funding round led by StepStone Group, bringing its total funding to over $160 million to enhance its AI capabilities and expand its platform.
- The company has notable partnerships, including a recent collaboration with Preceptis Medical to support the market launch of the Hummingbird Tympanostomy Tube System, leveraging its comprehensive market data and AI-driven insights.
- AcuityMD's ideal buyers are commercial teams within MedTech companies seeking to streamline their market intelligence and execution processes, addressing the pain of manual research and disconnected tools in commercial operations.
AcuityMD's workforce is organized across 10 departments, with the largest being Sales at 32 employees, followed closely by Engineering and Information Technology, each with 22 and 19 employees, respectively. The balanced distribution across departments indicates a strong emphasis on both technical and operational capabilities. Notably, the Community and Social Services department, comprising 17 employees, highlights the company's commitment to social impact alongside its core business functions.
The company operates across 41 locations, with a notable concentration in major urban centers. Boston, MA, serves as the headquarters with 9 employees, while San Francisco, CA, and New York, NY, follow with 8 and 7 employees, respectively. The significant 'Other' category, accounting for 62 employees, suggests a distributed workforce model, allowing for flexibility and access to diverse talent across various regions.
